Scarica l'app Stockscreener
14.63
1.67%
0.24
Dopo l'orario di chiusura:
14.74
0.11
+0.75%
Precedente Chiudi:
$14.39
Aprire:
$14.18
Volume 24 ore:
574.60K
Relative Volume:
0.64
Capitalizzazione di mercato:
$1.54B
Reddito:
-
Utile/perdita netta:
$-115.88M
Rapporto P/E:
-9.4582
EPS:
-1.5468
Flusso di cassa netto:
$-104.72M
1 W Prestazione:
+6.55%
1M Prestazione:
-0.81%
6M Prestazione:
-48.30%
1 anno Prestazione:
-30.93%
Intervallo 1D:
$14.01
$14.66
Intervallo di 1 settimana:
$13.34
$14.66
Portata 52W:
$10.60
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Nome
Edgewise Therapeutics Inc
Settore
Industria
Telefono
720-262-7002
Indirizzo
1715 38TH ST, BOULDER
Confronta EWTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
14.63 | 1.51B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2025-04-30 | Iniziato | Guggenheim | Buy |
| 2025-04-02 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-01-22 | Iniziato | Stifel | Hold |
| 2024-11-22 | Iniziato | Evercore ISI | Outperform |
| 2024-03-07 | Iniziato | Piper Sandler | Overweight |
| 2023-05-01 | Iniziato | Truist | Buy |
| 2022-08-25 | Downgrade | Goldman | Neutral → Sell |
| 2022-04-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-01-28 | Iniziato | Goldman | Neutral |
Mostra tutto
Edgewise Therapeutics Inc Borsa (EWTX) Ultime notizie
What analysts say about Edgewise Therapeutics Inc. stockOutstanding capital growth - PrintWeekIndia
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Edgewise Therapeutics, Inc. (EWTX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
What drives Edgewise Therapeutics Inc. stock priceFast-track wealth growth - Autocar Professional
Edgewise Therapeutics Inc. Stock Analysis and ForecastMarket-leading growth rates - Autocar Professional
Becker Muscular Dystrophy Pipeline 2025: Key Companies, MOA, - openPR.com
BlackRock, Inc. Reduces Stake in Edgewise Therapeutics Inc. - GuruFocus
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by Arizona State Retirement System - Defense World
Is Edgewise Therapeutics Inc. a good long term investmentConsistently superior profits - jammulinksnews.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Edgewise Therapeutics, Inc. (EWTX) And Encourages Investors to Reach Out - ACCESS Newswire
Readystate Asset Management LP Boosts Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc.EWTX - MarketScreener
Jennison Associates LLC Purchases New Stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Edgewise Therapeutics, Inc. (EWTX) And Encourages Stockholders to Reach Out - ACCESS Newswire
EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - The Globe and Mail
When is the best time to buy Edgewise Therapeutics Inc. stockSmart Growth Low Risk Picks - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc.EWTX - cnhinews.com
why edgewise therapeutics inc. stock attracts strong analyst attentionFree Professional Portfolio Management - Newser
What makes Edgewise Therapeutics Inc. stock price move sharplyQuick Profit Idea Stream - Newser
How Edgewise Therapeutics Inc. stock performs during market volatilityShort Squeeze Radar - Newser
Why Edgewise Therapeutics Inc. stock attracts strong analyst attentionSmart Money Signals - Newser
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Up 7.9%Time to Buy? - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Edgewise Therapeutics Reports Positive Results for Muscular Dystrophy Treatment - MSN
(EWTX) Trading Report - news.stocktradersdaily.com
User - FinancialContent
HC Wainwright Initiates Edgewise Therapeutics With Buy Rating, $42 Price Target - MarketScreener
Edgewise Therapeutics (EWTX) Initiated with Buy Rating by HC Wainwright | EWTX Stock News - GuruFocus
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownHere's Why - MarketBeat
Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Vertex Pharmaceuticals (VRTX) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Edgewise Therapeutics (EWTX) Advances Sevasemten Trials in Muscu - GuruFocus
Edgewise Therapeutics Shares Drop After FDA Withholds Accelerated Approval for Muscle Disorder Drug - MSN
Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies - WV News
Edgewise Therapeutics Inc Azioni (EWTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):